An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Phase of Trial: Phase IV
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms REINFORCE
- Sponsors Allergan
- 31 May 2016 Status changed from active, no longer recruiting to completed.
- 26 Apr 2016 Data will be presented at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), as per Allergan media release.
- 11 Sep 2015 Planned End Date changed from 1 Mar 2017 to 1 May 2016 as reported by ClinicalTrials.gov record.